Skip to main content
CStone Pharmaceuticals logo

CStone Pharmaceuticals — Investor Relations & Filings

Ticker · 2616 ISIN · KYG2588M1006 LEI · 300300095A57F80T2461 HKEX Manufacturing
Open in API
Filings indexed 3,374 across all filing types
Latest filing 2022-12-06 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 2616

About CStone Pharmaceuticals

http://www.cstonepharma.com

CStone Pharmaceuticals is an innovation-driven biopharmaceutical company focused on the research, development, and commercialization of anti-tumor drugs. The company is dedicated to addressing the unmet medical needs of cancer patients globally. Its core therapeutic focus is on innovative immuno-oncology and molecularly targeted therapies. The R&D pipeline is strategically balanced, featuring potential first-in-class or best-in-class assets, including Antibody-Drug Conjugates (ADC) and multi-specific antibodies. CStone has successfully launched four innovative drugs and secured multiple New Drug Application and indication approvals.

Recent filings

Filing Released Lang Actions
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 NOVEMBER 2022
Regulatory Filings Classification · 95% confidence The document is a detailed monthly report on movements in securities, specifically focusing on changes in authorized and issued share capital, share options exercised, and confirmations related to share issuance. It is addressed to the Hong Kong Exchanges and Clearing Limited and references compliance with the Exchange Listing Rules. The content is regulatory in nature, reporting share capital changes and share option exercises for the month ended 30 November 2022. It does not contain financial statements, management discussion, or earnings data. It is not an announcement of a report but a regulatory submission detailing share capital movements. This fits the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2022-12-06 English
VOLUNTARY ANNOUNCEMENT - CSTONE PRESENTS UPDATED DATA FOR GAVRETO (PRALSETINIB) IN CHINESE PATIENTS WITH RET-FUSION POSITIVE NON-SMALL CELL LUNG CANCER AT ESMO ASIA CONGRESS 2022
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CStone Pharmaceuticals presenting updated clinical data for their drug GAVRETO (pralsetinib) in Chinese patients with RET-fusion positive non-small cell lung cancer. It includes detailed efficacy and safety data from a clinical study (ARROW study), regulatory status updates, and background information about the drug and company. The document is not a full financial report, audit, or earnings release. It is not a regulatory filing or certification, nor is it a presentation or call transcript. It is a corporate announcement focused on clinical trial results and drug development progress, which does not fit into categories like Annual Report, Interim Report, or Capital Update. Given the nature and content, this is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about clinical data and drug status that does not fit other specific categories.
2022-12-05 English
Monthly Returns
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 30 November 2022. It details movements in authorised/registered share capital, issued shares, share options, and confirms no new securities were issued during the month. The document is a regulatory submission to the Hong Kong Exchanges and Clearing Limited, reporting share capital and share issuance movements for a specific month. It does not contain financial statements, management discussion, or earnings data. It is not an annual or interim report, nor an earnings release or investor presentation. It is a regulatory filing reporting share capital movements and confirmations related to securities issuance. Therefore, it fits best under Regulatory Filings (RNS). The document length (9038 characters) and detailed tabular data support this classification with high confidence.
2022-12-01 English
VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING OF THE COMPANY BY THE CHIEF EXECUTIVE OFFICER AND EXECUTIVE DIRECTOR
Director's Dealing Classification · 95% confidence The document is a voluntary announcement regarding an increase in shareholding by the Chief Executive Officer and Executive Director of the company. It details the purchase of shares by Dr. Jianxin Yang and his confidence in the company's future. There are no financial statements, regulatory certifications, or detailed financial data present. The document is an announcement about insider share transactions rather than a full report or regulatory filing. This fits the definition of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades). The document length is 4707 characters, which is consistent with an announcement rather than a full report. Therefore, the correct classification is DIRS with high confidence.
2022-11-21 English
ANNOUNCEMENT ON THE PARTICIPATION IN 2022 ONLINE COLLECTIVE RECEPTION ACTIVITY FOR INVESTORS
Regulatory Filings Classification · 85% confidence The document is an announcement about the company's participation in a 2022 online collective reception activity for investors. It describes the event's purpose, time, mode, participants, and how investors can participate. There is no financial data, no detailed report, no voting results, no management changes, no earnings information, and no regulatory filings or certifications. The document is essentially an announcement of an investor communication event, not a report or transcript. Given the nature of the content, it best fits the category of Investor Presentation (IP) as it focuses on investor relations and communication, although it is not a detailed presentation file, it is closest to that category compared to others. However, since it is an announcement of participation in an investor event rather than a presentation itself, and it is not a report publication or regulatory filing, the best fit is Regulatory Filings (RNS) as a general announcement that does not fit other categories better.
2022-11-14 English
INSIDE INFORMATION ANNOUNCEMENT - CSTONE ANNOUNCED REGISTRATIONAL STUDY OF SUGEMALIMAB FOR FIRST-LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC GASTRIC ADENOCARCINOMA/GASTROESOPHAGEAL JUNCTION
Regulatory Filings Classification · 95% confidence The document is an announcement from CStone Pharmaceuticals regarding positive results from a registrational clinical study (GEMSTONE-303) of their drug sugemalimab for gastric adenocarcinoma. It is labeled as an "INSIDE INFORMATION ANNOUNCEMENT" and is issued pursuant to the Listing Rules of the Hong Kong Stock Exchange. The content focuses on clinical trial results, regulatory status, and forward-looking statements. There are no financial statements, quarterly or annual results, or detailed financial data presented. The document is not a full financial report, earnings release, or management discussion. It is a regulatory announcement disclosing material clinical trial results that could impact the company's stock price and investor decisions. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Investor Presentation. It is a regulatory announcement of material inside information under stock exchange rules. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback category for general regulatory announcements and disclosures that do not fit other specific categories.
2022-11-11 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.